Arcutis Biotherapeutics Inc (ARQT)

01:40 AM

Arcutis Biotherapeutics initiated with a Neutral at Goldman Sachs - TipRanks

01:40 AM

Jul 23, 2025

Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 - The Manila Times

Jul 23, 2025

Jul 23, 2025

Is Arcutis Biotherapeutics (NASDAQ:ARQT) Using Too Much Debt? - 富途牛牛

Jul 23, 2025

Jul 23, 2025

What analysts say about Arcutis Biotherapeutics Inc. stockFree Investment Community - Autocar Professional

Jul 23, 2025

Jul 22, 2025

Is Arcutis Biotherapeutics Inc. a good long term investmentDynamic growth stocks - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Arcutis Biotherapeutics Inc. Stock Analysis and ForecastExponential return rates - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

What drives Arcutis Biotherapeutics Inc. stock priceAccelerated wealth building - jammulinksnews.com

Jul 22, 2025

Jul 21, 2025

Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth - Investing.com India

Jul 21, 2025

Jul 20, 2025

(ARQT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Jul 20, 2025

Jul 17, 2025

Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study - TipRanks

Jul 17, 2025

Jul 15, 2025

Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load? - simplywall.st

Jul 15, 2025

Jul 14, 2025

Arcutis Bio EVP Burnett sells $432k in ARQT stock after option exercise - Investing.com Canada

Jul 14, 2025

Jul 14, 2025

Arcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis - MSN

Jul 14, 2025

Jul 11, 2025

FDA News and Decisions: Midyear Updates - Dermatology Times

Jul 11, 2025

Jul 10, 2025

Arcutis Biotherapeutics Stock Scores RS Rating Upgrade - MSN

Jul 10, 2025

Jul 09, 2025

(ARQT) Investment Analysis - news.stocktradersdaily.com

Jul 09, 2025

Jul 09, 2025

Arcutis Biotherapeutics - WBFF

Jul 09, 2025

Jul 09, 2025

Uncovering Plaque Psoriasis: Exploring New FDA-Approved Topical Treatment - ABC Action News

Jul 09, 2025

Jul 04, 2025

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 04, 2025

Jul 03, 2025

Morgan Stanley assumes coverage of Arcutis Biotherapeutics stock with Overweight rating - Investing.com Nigeria

Jul 03, 2025

Jul 03, 2025

Arcutis Awards Generous Stock Compensation Package: 14,000 RSUs for Two New Hires - Stock Titan

Jul 03, 2025

Jun 27, 2025

Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction (NASDAQ:ARQT) - Seeking Alpha

Jun 27, 2025

Jun 26, 2025

Arcutis Biotherapeutics (ARQT) Gains Strong AAD Recommendation for ZORYVE Cream | ARQT Stock News - GuruFocus

Jun 26, 2025

Jun 26, 2025

ZORYVE Becomes Only Branded Topical to Earn Strong AAD Recommendation for Atopic Dermatitis - Stock Titan

Jun 26, 2025

Jun 25, 2025

Arcutis Biotherapeutics: Another Approval Under Their Belt - Seeking Alpha

Jun 25, 2025

Jun 23, 2025

Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st

Jun 23, 2025

Jun 18, 2025

When (ARQT) Moves Investors should Listen - news.stocktradersdaily.com

Jun 18, 2025

Jun 18, 2025

Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long - Yahoo Finance

Jun 18, 2025

Jun 17, 2025

Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials - MSN

Jun 17, 2025

Jun 17, 2025

Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks

Jun 17, 2025

Jun 12, 2025

Arcutis: Out Of The Woods, Ready For Commercialization - Seeking Alpha

Jun 12, 2025

Jun 11, 2025

10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey

Jun 11, 2025

Jun 11, 2025

First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis - Yahoo Finance

Jun 11, 2025